HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of the effects of fourth-generation fluoroquinolones on corneal re-epithelialization in rabbit eyes.

AbstractBACKGROUND:
Gatifloxacin and moxifloxacin ophthalmic solutions are frequently prescribed for antimicrobial prophylaxis following cataract and corneal refractive surgeries, although the use of topical antibiotics is likely to interfere with wound healing in the immediate postoperative period. A potential factor that may influence rates of wound healing or corneal re-epithelialization is how the solutions are preserved. Gatifloxacin is preserved with 0.005% benzalkonium chloride, whereas moxifloxacin is unpreserved. The purpose of this study was to evaluate the effects of commercially prepared topical gatifloxacin and moxifloxacin on corneal re-epithelialization in rabbit eyes.
METHODS:
In this randomized, prospective, controlled study, 17 New Zealand white rabbits underwent bilateral corneal de-epithelialization procedures using 20% alcohol contained within a 6 mm trephine. Postoperatively, eyes were randomly assigned to receive either gatifloxacin 0.3%, moxifloxacin 0.5%, or balanced salt solution (BSS) four times daily. Each 6 hours during the first 2 days, and every 12 hours thereafter slit-lamp measurements and corneal photography were performed, enabling de-epithelialized surface areas to be calculated via EPCO 2000 computer analysis.
RESULTS:
Gatifloxacin (n = 12) and moxifloxacin (n = 13) treated eyes had a statistically significant (p = 0.036) delay in epithelial healing relative to controls (BSS, n = 8). Healing rates of gatifloxacin and moxifloxacin treated eyes were not significantly different (p = 0.545).
CONCLUSIONS:
We found no significant difference in re-epithelialization rates following topical application of gatifloxacin 0.3% and moxifloxacin 0.5%. Both antibiotic solutions delayed healing compared to BSS. Our analysis suggests that there was no apparent added epithelial toxicity due to the presence of BAK in the gatifloxacin preparation.
AuthorsMajid Moshirfar, Jesse Chew, Liliana Werner, Jay J Meyer, Brian Hunter, Scott Stevens, Mike Jensen, Guy Kleinmann, Nick Mamalis
JournalGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 246 Issue 10 Pg. 1455-61 (Oct 2008) ISSN: 0721-832X [Print] Germany
PMID18642018 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Infective Agents
  • Aza Compounds
  • Benzalkonium Compounds
  • Fluoroquinolones
  • Ophthalmic Solutions
  • Preservatives, Pharmaceutical
  • Quinolines
  • Ethanol
  • Gatifloxacin
  • Moxifloxacin
Topics
  • Administration, Topical
  • Animals
  • Anti-Infective Agents (administration & dosage, pharmacology)
  • Aza Compounds (administration & dosage, pharmacology)
  • Benzalkonium Compounds (administration & dosage, pharmacology)
  • Corneal Diseases (chemically induced, diagnosis, drug therapy)
  • Disease Models, Animal
  • Epithelium, Corneal (drug effects, pathology)
  • Ethanol
  • Female
  • Fluoroquinolones (administration & dosage, pharmacology)
  • Gatifloxacin
  • Image Processing, Computer-Assisted
  • Male
  • Moxifloxacin
  • Ophthalmic Solutions (administration & dosage, pharmacology)
  • Preservatives, Pharmaceutical (administration & dosage, pharmacology)
  • Prospective Studies
  • Quinolines (administration & dosage, pharmacology)
  • Rabbits
  • Wound Healing (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: